Portfolio Holdings Detail for ISIN IE00B3VWM098

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE

Holdings detail for HAE

Show aggregate HAE holdings

News associated with HAE

Haemonetics Corporation (NYSE:HAE) Short Interest Up 41.9% in August

Haemonetics Corporation (NYSE:HAE – Get Free Report) was the recipient of a large growth in short interest during the month of August. As of August 15th, there was short interest totaling 4,370,000 shares, a growth of 41.9% from the July 31st total of 3,080,000 shares. Approximately 9.2% of the company’s stock are short sold. Based […] - 2025-09-10 04:58:58

Haemonetics (NYSE:HAE) Price Target Lowered to $70.00 at Mizuho

Haemonetics (NYSE:HAE – Free Report) had its target price reduced by Mizuho from $90.00 to $70.00 in a research report released on Friday,Benzinga reports. They currently have an outperform rating on the medical instruments supplier’s stock. A number of other equities analysts also recently commented on the stock. Raymond James Financial reiterated a “strong-buy” rating […] - 2025-08-11 02:56:42

Brokerages Set Haemonetics Corporation (NYSE:HAE) Target Price at $97.30

Shares of Haemonetics Corporation (NYSE:HAE – Get Free Report) have been assigned a consensus recommendation of “Buy” from the eleven analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and two have assigned a strong buy recommendation […] - 2025-08-06 02:30:53

How The Pieces Add Up: SPMD Targets $63

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-28 08:27:27

Arizona State Retirement System Trims Position in Haemonetics Corporation (NYSE:HAE)

Arizona State Retirement System cut its holdings in shares of Haemonetics Corporation (NYSE:HAE – Free Report) by 3.0% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 14,407 shares of the medical instruments supplier’s stock after selling 446 shares during the quarter. Arizona State Retirement System’s holdings in Haemonetics were worth $916,000 at […] - 2025-07-21 06:12:11

Principal Financial Group Inc. Acquires 2,160 Shares of Haemonetics Corporation (NYSE:HAE)

Principal Financial Group Inc. lifted its stake in Haemonetics Corporation (NYSE:HAE – Free Report) by 1.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 158,894 shares of the medical instruments supplier’s stock after purchasing an additional 2,160 shares during […] - 2025-07-15 05:12:49

Haemonetics (NYSE:HAE) Raised to Buy at Citigroup

Haemonetics (NYSE:HAE – Get Free Report) was upgraded by stock analysts at Citigroup from a “neutral” rating to a “buy” rating in a research note issued to investors on Wednesday, MarketBeat.com reports. The brokerage presently has a $90.00 target price on the medical instruments supplier’s stock. Citigroup’s target price points to a potential upside of […] - 2025-07-11 02:20:48

Haemonetics Corporation (NYSE:HAE) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Haemonetics Corporation (NYSE:HAE – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have given a buy recommendation and two […] - 2025-07-09 04:53:34

KBC Group NV Grows Holdings in Haemonetics Corporation (NYSE:HAE)

KBC Group NV raised its position in Haemonetics Corporation (NYSE:HAE – Free Report) by 19.9% during the first quarter, Holdings Channel.com reports. The firm owned 2,417 shares of the medical instruments supplier’s stock after buying an additional 401 shares during the period. KBC Group NV’s holdings in Haemonetics were worth $154,000 at the end of […] - 2025-07-07 04:48:46

Vontobel Holding Ltd. Has $1.01 Million Holdings in Haemonetics Corporation (NYSE:HAE)

Vontobel Holding Ltd. increased its position in shares of Haemonetics Corporation (NYSE:HAE – Free Report) by 21.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,839 shares of the medical instruments supplier’s stock after acquiring an additional 2,828 shares during the period. Vontobel […] - 2025-07-06 06:01:06

Analysts Predict 15% Gains Ahead For IJJ

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-26 12:59:11

Haemonetics Co. (NYSE:HAE) Shares Bought by Rhumbline Advisers

Rhumbline Advisers increased its stake in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 1.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 161,123 shares of the medical instruments supplier’s stock after acquiring an additional 1,861 shares during […] - 2025-06-10 04:54:58

Two Sigma Investments LP Decreases Holdings in Haemonetics Co. (NYSE:HAE)

Two Sigma Investments LP trimmed its stake in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 24.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 58,799 shares of the medical instruments supplier’s stock after selling 18,675 shares during the quarter. Two Sigma Investments LP’s holdings in Haemonetics were worth $4,591,000 at the end […] - 2025-05-28 05:52:51

Nuveen Asset Management LLC Lowers Stock Holdings in Haemonetics Co. (NYSE:HAE)

Nuveen Asset Management LLC lowered its stake in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 11.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 161,452 shares of the medical instruments supplier’s stock after selling 19,887 shares during the quarter. […] - 2025-05-27 04:44:56

Analysts Set Haemonetics Co. (NYSE:HAE) PT at $97.89

Shares of Haemonetics Co. (NYSE:HAE – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have issued a buy recommendation and […] - 2025-05-23 03:14:52

Nomura Holdings Inc. Invests $519,000 in Haemonetics Co. (NYSE:HAE)

Nomura Holdings Inc. purchased a new position in Haemonetics Co. (NYSE:HAE – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 6,652 shares of the medical instruments supplier’s stock, valued at approximately $519,000. A number of other hedge funds have also recently made changes […] - 2025-05-22 06:48:56

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,084 Shares of Haemonetics Co. (NYSE:HAE)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 3.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,570 shares of the medical instruments supplier’s stock after purchasing an additional 1,084 shares during the […] - 2025-05-22 05:50:49

Captrust Financial Advisors Grows Position in Haemonetics Co. (NYSE:HAE)

Captrust Financial Advisors raised its position in Haemonetics Co. (NYSE:HAE – Free Report) by 14.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,872 shares of the medical instruments supplier’s stock after purchasing an additional 624 shares during the […] - 2025-05-20 04:50:49

Haemonetics (NYSE:HAE) Lowered to “Hold” Rating by StockNews.com

Haemonetics (NYSE:HAE – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Tuesday. HAE has been the topic of several other reports. Bank of America lowered Haemonetics from a “neutral” rating to an “underperform” rating and cut their target price […] - 2025-05-15 02:56:49

Schonfeld Strategic Advisors LLC Reduces Position in Haemonetics Co. (NYSE:HAE)

Schonfeld Strategic Advisors LLC lessened its stake in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 13.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,266 shares of the medical instruments supplier’s stock after selling 672 shares during the period. […] - 2025-05-13 05:38:48

Stifel Financial Corp Grows Position in Haemonetics Co. (NYSE:HAE)

Stifel Financial Corp lifted its position in Haemonetics Co. (NYSE:HAE – Free Report) by 7.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,776 shares of the medical instruments supplier’s stock after purchasing an additional 1,006 shares during the quarter. Stifel […] - 2025-05-09 05:26:56

Analysts Set Haemonetics Co. (NYSE:HAE) Price Target at $101.22

Haemonetics Co. (NYSE:HAE – Get Free Report) has received an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have given a buy recommendation and one has issued […] - 2025-04-28 02:39:01

Envestnet Asset Management Inc. Buys 4,217 Shares of Haemonetics Co. (NYSE:HAE)

Envestnet Asset Management Inc. boosted its stake in Haemonetics Co. (NYSE:HAE – Free Report) by 9.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 48,068 shares of the medical instruments supplier’s stock after purchasing an additional 4,217 shares during the […] - 2025-04-25 04:40:56

Bank of Montreal Can Sells 12,518,398 Shares of Haemonetics Co. (NYSE:HAE)

Bank of Montreal Can decreased its stake in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 99.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 7,933 shares of the medical instruments supplier’s stock after selling 12,518,398 shares during the quarter. Bank of Montreal Can’s holdings in Haemonetics were worth $619,000 as of […] - 2025-04-21 05:18:52

Federated Hermes Inc. Trims Holdings in Haemonetics Co. (NYSE:HAE)

Federated Hermes Inc. reduced its holdings in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 10.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 3,554 shares of the medical instruments supplier’s stock after selling 436 shares during the period. Federated Hermes Inc.’s holdings in Haemonetics […] - 2025-04-18 04:59:07

Haemonetics Co. (NYSE:HAE) Holdings Raised by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lifted its position in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 16.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,963 shares of the medical instruments supplier’s stock after acquiring an additional 979 […] - 2025-04-09 05:42:56

KLP Kapitalforvaltning AS Makes New Investment in Haemonetics Co. (NYSE:HAE)

KLP Kapitalforvaltning AS acquired a new stake in Haemonetics Co. (NYSE:HAE – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund acquired 10,100 shares of the medical instruments supplier’s stock, valued at approximately $789,000. A number of other hedge funds also recently modified their holdings of HAE. Wellington Management Group LLP raised its […] - 2025-04-01 05:14:58

15,294 Shares in Haemonetics Co. (NYSE:HAE) Bought by Natixis Advisors LLC

Natixis Advisors LLC acquired a new stake in shares of Haemonetics Co. (NYSE:HAE – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund acquired 15,294 shares of the medical instruments supplier’s stock, valued at approximately $1,194,000. A number of other hedge funds have also recently modified their holdings of HAE. Parkside Financial Bank […] - 2025-03-26 05:54:45

Zurcher Kantonalbank Zurich Cantonalbank Acquires 1,202 Shares of Haemonetics Co. (NYSE:HAE)

Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Haemonetics Co. (NYSE:HAE – Free Report) by 10.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,460 shares of the medical instruments supplier’s stock after acquiring an additional 1,202 shares during the period. Zurcher […] - 2025-03-21 06:08:54

Needham & Company LLC Has Lowered Expectations for Haemonetics (NYSE:HAE) Stock Price

Haemonetics (NYSE:HAE – Get Free Report) had its target price cut by stock analysts at Needham & Company LLC from $108.00 to $104.00 in a report issued on Tuesday, Marketbeat reports. The brokerage currently has a “buy” rating on the medical instruments supplier’s stock. Needham & Company LLC’s target price indicates a potential upside of […] - 2025-03-20 04:28:54

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc HAE holdings

Date	Number of HAE Shares Held	Base Market Value of HAE Shares	Local Market Value of HAE Shares	Change in HAE Shares Held	Change in HAE Base Value	Current Price per HAE Share Held	Previous Price per HAE Share Held
2025-09-26 (Friday)	36,166	USD 1,742,116	USD 1,742,116
2025-09-25 (Thursday)	36,166	USD 1,724,033	USD 1,724,033	0	USD -106,328	USD 47.67	USD 50.61
2025-09-24 (Wednesday)	36,166	USD 1,830,361	USD 1,830,361
2025-09-17 (Wednesday)	35,932	USD 1,794,803	USD 1,794,803	0	USD -38,448	USD 49.95	USD 51.02
2025-09-16 (Tuesday)	35,932	USD 1,833,251	USD 1,833,251
2025-09-12 (Friday)	35,698	USD 1,863,436	USD 1,863,436
2025-09-11 (Thursday)	35,698	USD 1,909,129	USD 1,909,129

Share Trades of HAE by Blackrock for IE00B3VWM098

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-08-21	SELL	-117			53.980*		70.12 Profit of 8,204 on sale
2025-07-31	BUY	351			74.040*		70.19
2025-07-28	SELL	-117			74.660*		70.09 Profit of 8,201 on sale
2025-06-30	SELL	-234			74.610*		69.49 Profit of 16,260 on sale
2025-06-25	SELL	-117			73.400*		69.39 Profit of 8,119 on sale
2025-06-20	SELL	-234			71.080*		69.34 Profit of 16,225 on sale
2025-05-30	SELL	-6,976			67.710*		69.24 Profit of 482,998 on sale
2025-05-23	BUY	141			66.060*		69.33
2025-05-19	SELL	-141			69.360*		69.38 Profit of 9,782 on sale
2025-05-15	SELL	-423			69.380*		69.37 Profit of 29,343 on sale
2025-05-12	SELL	-142			70.230*		69.37 Profit of 9,850 on sale
2025-05-09	SELL	-142			68.190*		69.38 Profit of 9,852 on sale
2025-04-30	SELL	-142			63.020*		69.74 Profit of 9,904 on sale
2025-04-24	SELL	-284			61.920*		70.03 Profit of 19,887 on sale
2025-04-22	BUY	1,432			59.150*		70.24
2025-04-17	SELL	-136			57.170*		70.66 Profit of 9,609 on sale
2025-04-15	SELL	-408			58.300*		70.94 Profit of 28,944 on sale
2025-04-14	SELL	-408			59.420*		71.07 Profit of 28,996 on sale
2025-04-09	SELL	-544			61.030*		71.44 Profit of 38,864 on sale
2025-04-07	SELL	-952			58.950*		71.77 Profit of 68,321 on sale
2025-04-04	SELL	-1,360			60.880*		71.89 Profit of 97,775 on sale
2025-03-31	BUY	136			63.550*		72.20
2025-03-19	SELL	-272			65.230*		73.07 Profit of 19,876 on sale
2025-03-14	SELL	-816			65.520*		73.41 Profit of 59,906 on sale
2025-03-13	SELL	-272			65.930*		73.52 Profit of 19,998 on sale
2025-03-12	SELL	-4,624			65.680*		73.63 Profit of 340,488 on sale
2025-03-07	SELL	-272			68.700*		73.88 Profit of 20,096 on sale
2025-03-06	SELL	-414			67.200*		73.99 Profit of 30,631 on sale
2025-03-03	SELL	-138			65.080*		74.37 Profit of 10,263 on sale
2025-02-28	SELL	-2,721			65.500*		74.51 Profit of 202,755 on sale
2025-02-26	SELL	-142			64.930*		74.85 Profit of 10,628 on sale
2025-02-25	SELL	-426			65.390*		75.01 Profit of 31,954 on sale
2025-02-18	BUY	710			64.090*		76.04
2025-02-13	BUY	142			62.290*		76.87
2025-02-12	BUY	142			61.310*		77.18
2025-02-11	BUY	426			61.540*		77.51
2025-02-06	BUY	1,278			62.990*		78.61
2025-01-27	BUY	142			71.290*		80.66
2024-12-30	BUY	710			76.600*		81.38
2024-12-06	BUY	568			81.190*		81.25
2024-12-05	BUY	142			80.670*		81.27
2024-12-04	BUY	710			83.510*		81.19
2024-11-29	BUY	710			87.470*		80.53
2024-11-27	BUY	568			87.890*		79.89
2024-11-26	BUY	142			88.530*		79.49
2024-11-21	BUY	710			85.430*		78.39
2024-11-20	BUY	426			84.920*		78.03
2024-11-18	BUY	1,704			88.170*		76.97
2024-11-12	BUY	1,136			93.380*		75.87
2024-11-08	BUY	710			87.420*		75.05
2024-11-07	BUY	2,115			86.530*		74.17
2024-11-06	BUY	282			78.160*		73.83
2024-10-31	BUY	141			71.160*		74.36

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of HAE

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer